Roche Holding AG (LON:0QQ6)
317.00
+2.00 (0.63%)
At close: Feb 21, 2025
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
532.69K GBP
Profits / Employee
70.66K GBP
Market Cap
210.56B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 103,249 | -356 | -0.34% |
Dec 31, 2023 | 103,605 | -8 | -0.01% |
Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
Dec 31, 2021 | 100,920 | -545 | -0.54% |
Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
Hikma Pharmaceuticals | 9,100 |
ConvaTec Group | 10,136 |
HUTCHMED (China) | 1,988 |
Genus | 3,500 |
Roche Holding AG News
- 3 days ago - Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology - GlobeNewsWire
- 4 days ago - Roche goes beyond diagnostics innovation and builds partnerships for proactive healthcare - South China Morning Post
- 4 days ago - Yemaachi Biotechnology Launches The African Cancer Atlas, in Partnership with Roche - Business Wire
- 10 days ago - Roche upgraded by UBS to buy on growth outlook - Seeking Alpha
- 11 days ago - FDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA) - GlobeNewsWire
- 11 days ago - FDA Approves Genentech's Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA) - Business Wire
- 16 days ago - New England Journal of Medicine publishes new data for Roche's Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis - GlobeNewsWire
- 16 days ago - New England Journal of Medicine Publishes New Data for Genentech's Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis - Business Wire